Cargando…
Dose- and time-dependent tolerability and efficacy of organo-osmium complex FY26 and its tissue pharmacokinetics in hepatocarcinoma-bearing mice
The organo-osmium complex [Os(II)(ɳ(6)-p-cym)(PhAzPy-NMe(2))I](+) (FY26) exhibits promising in vitro antitumour activity against mouse hepatocarcinoma Hepa1–6 and other mouse or human cancer cell lines. Here, we drastically enhance water solubility of FY26 through the replacement of the PF(6)(−) cou...
Autores principales: | Kumar, Swati A, Needham, Russell J, Abraham, Kristin, Bridgewater, Hannah E, Garbutt, Lauren A, Xandri-Monje, Helena, Dallmann, Robert, Perrier, Sebastien, Sadler, Peter J, Lévi, Francis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7853623/ https://www.ncbi.nlm.nih.gov/pubmed/33595653 http://dx.doi.org/10.1093/mtomcs/mfaa003 |
Ejemplares similares
-
In‐Cell Activation of Organo‐Osmium(II) Anticancer Complexes
por: Needham, Russell J., et al.
Publicado: (2016) -
Tracking Reactions of Asymmetric Organo‐Osmium Transfer Hydrogenation Catalysts in Cancer Cells
por: Bolitho, Elizabeth M., et al.
Publicado: (2021) -
Easy To Synthesize, Robust Organo‐osmium Asymmetric Transfer Hydrogenation Catalysts
por: Coverdale, James P. C., et al.
Publicado: (2015) -
NMR studies of group 8 metallodrugs: (187)Os-enriched organo-osmium half-sandwich anticancer complex
por: Needham, Russell J., et al.
Publicado: (2021) -
Osmium–arene complexes with high potency towards Mycobacterium tuberculosis
por: Coverdale, James P C, et al.
Publicado: (2021)